Time (UTC+8) Topic / 主題 Speaker / 講者 Slides / 簡報 Online Conference / 線上會議
17:00 - 17:50 Abstract oral presentation
18:00 - 18:30 【TBCS-GBCC Joint Session】Opening
18:10 - 18:40 【TBCS-GBCC Joint Session】Overcome the gap between the reality and international guideline: Korea’s view
18:40 - 19:10 【TBCS-GBCC Joint Session】Overcome the gap between the reality and international guideline: Taiwan’s view
19:10 - 20:20 【TBCS-GBCC Joint Session】Round table discussion
Time (UTC+8) Topic / 主題 Speaker / 講者 Slides / 簡報 Online Conference / 線上會議
08:15 - 08:30 Opening Remark
08:30 - 09:00 What can we contribute to breast cancer in Taiwan ? Mien-Chie Hung
09:00 - 09:30 New horizon of TNBC: clinical outcomes and perspective of A Novel Trop-2 Antibody-Drug conjugate Hope S. Rugo
09:30 - 10:00 To whom should adjuvant PARP inhibitors be offered? Charles E. Geyer
10:00 - 10:30 Coffee Break
10:30 - 11:00 The changing treatment landscape for HR+HER2-mBC patient with CDKi Dejan Juric
11:00 - 11:30 Treatment options of CDK4&6i, S-1, and PARP-i on HR+ early breast cancer: Japan experience Hiroko Masuda
11:30 - 11:50 Mucinous carcinoma Yoon-Sim Yap
11:50 - 12:20 Metaplatic carcinoma of breast: biology, challenges, and strategic direction Ching-Hung Lin
12:20 - 13:00 【Luncheon Symposium】Thinking outside of the box? What are the possible options for metastatic breast cancer Wei-Wu Chen
13:00 - 13:30 Break
13:30 - 14:00 Maximizing clinical benefit of atezolizumab in triple negative breast cancer Chun-Yu Liu
14:00 - 14:30 The Benefit of Extended Adjuvant Therapy in HER2+ eBC Patients with High Recurrence Risk Diana Lüftner
14:30 - 15:00 Genetic testing for hereditary breast cancer - what we’ve learned today and what to do tomorrow Wen-Ling Kuo
15:00 - 15:30 Coffee Break
15:30 - 16:00 Raising the bar for patients with HR+/HER2- Early Breast Cancer Nadia Harbeck
16:00 - 16:30 Unsolved questions in CDK4/6i mBC setting Fatima Cardoso
16:30 - 17:00 HER2 dual blockade treatment benefit on eBC patient survival and Singapore experience with FlexCare Soo Chin Lee
17:00 - 17:30 Past, present and future of HER2+ breast cancer treatment Paul Cornes
Time (UTC+8) Topic / 主題 Speaker / 講者 Slides / 簡報 Online Conference / 線上會議
08:20 - 08:50 Local-regional management after neoadjuvant therapy Laura Dominici
08:50 - 09:20 Local therapy for the primary site in De Novo Stage IV breast cancer Seema A. Khan
09:20 - 09:50 Recent progress of antibody-drug conjugate in breast cancer treatment Shanu Modi
09:50 - 10:20 Recent advances in Her2 directed therapy in Her2+ ABC Soo Chin Lee
10:20 - 10:40 Coffee Break
10:40 - 11:10 Experience sharing: how do we initiate and conduct large scale IIT Jee Hyun Kim
11:10 - 11:40 Identify unmet needs for improving care for patients with chemotherapy-induced neutropenia Chi-Cheng Huang
11:40 - 12:10 New Strategic Approach of Neoadjuvant in Early Breast Cancer Chin-Sheng Hung
12:10 - 12:50 【Luncheon Symposium】 Recent Roles of Vacuum assisted breast biopsy in Korea Sang-Won Kim
12:50 - 13:10 Break
13:10 - 13:40 Bone-targeted agents for the management of breast cancer patients with bone metastases Dwan-Ying Chang
13:40 - 14:00 Pseudocirrhosis: a unique presentation of liver metastasis in advanced breast cancer Wei-Li Ma
14:00 - 14:20 Coffee Break
14:20 - 14:50 Neoadjuvant chemotherapy backbone, which is the optimal option? Sibylle Loibl
14:50 - 15:20 The considerations about adjuvant treatment choices after neoadjuvant therapy Giampaolo Bianchini
15:20 - 15:50 Avoiding breast and axillary surgery after neoadjuvant therapy Joerg Heil
15:50 - 16:20 Adjuvant radiotherapy after neoadjuvant treatment Boon H. Chua
16:20 - 16:40 Panel Discussion
16:40 - 17:00 Award Ceremony & Closing